BP
CTSO icon

Ballentine Partners’s Cytosorbents Corp CTSO Stock Holding History

Ballentine Partners’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-20,000
Closed -$258K – 351
2018
Q3 		$258K Hold
20,000
– – 0.01% 288
2018
Q2 		$228K Buy
+20,000
New +$189K 0.01% 293

Other funds holding CTSO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

Ballentine Partners's CTSO Position: Q4 2018 in Review

Ballentine Partners sold out of Cytosorbents Corp (CTSO) in Q4 2018, closing a stake of 20,000 shares — an estimated $258K sold.

Ballentine Partners first reported a position in CTSO in Q2 2018 and held it in 2 quarters. The position peaked at $258K in Q3 2018. 85 funds tracked by Wall St. Rank hold CTSO as of Q4 2018.

  • Ballentine Partners reported no remaining Cytosorbents Corp position as of Q4 2018 after selling out during the quarter.
  • Ballentine Partners sold 20,000 Cytosorbents Corp shares in Q4 2018, an estimated $258K.
  • Ballentine Partners first reported a position in Cytosorbents Corp in Q2 2018 and held it in 2 quarters.
  • Ballentine Partners's Cytosorbents Corp position peaked at $258K in Q3 2018.
  • 85 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q4 2018.

Based on Ballentine Partners's 13F filing for Q4 2018, filed 4 Feb 2019.